Publication of phase I trial results – allogeneic adipose tissue-derived mesenchymal stromal/stem cell (ASCs) treatment in Sjögren’s syndrome

The clinical phase I trial evaluated the safety and feasibility of injecting allogeneic adipose tissue-derived mesenchymal stromal/stem cells (ASCs) into the lacrimal gland as a treatment of aqueous deficient dry eye disease (ADDE) Sjögrens syndrome.

The trial found injection of allogeneic ASCs produced using Cell2Cure´s patented technology into the lacrimal gland to be safe, feasible and well tolerated in seven patients. A single injection of allogeneic ASCs improved both signs and symptoms in patients with severe ADDE due to either primary or secondary Sjögren’s syndrome.

Full article link
Safety and feasibility of mesenchymal stem cell therapy in patients with aqueous deficient dry eye disease – PubMed